This is in agreement with previous published results where Sorafenib does not inhibit activation of the RAF/MEK/ERK pathway in all human tumor cell lines [33] a finding that highlights the importance of in-vivo assays for the quantification of drug effects. This evidence concerns the gene MAP2K7 and neoplasm.